HC Wainwright Issues Positive Estimate for PolyPid Earnings

PolyPid Ltd. (NASDAQ:PYPD) – Equities researchers at HC Wainwright increased their FY2024 earnings per share estimates for shares of PolyPid in a report released on Thursday, December 26th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($4.56) per share for the year, up from their prior estimate of ($4.83). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($4.39) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2024 earnings at ($0.90) EPS, Q1 2025 earnings at ($0.74) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.79) EPS.

Separately, Craig Hallum started coverage on PolyPid in a research note on Monday, November 4th. They issued a “buy” rating and a $10.00 price objective on the stock.

PolyPid Trading Up 9.0 %

PYPD stock opened at $3.15 on Monday. PolyPid has a twelve month low of $2.37 and a twelve month high of $9.20. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.17. The firm’s fifty day simple moving average is $3.24 and its two-hundred day simple moving average is $3.51. The stock has a market capitalization of $15.11 million, a price-to-earnings ratio of -0.40 and a beta of 1.33.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in PolyPid stock. Rosalind Advisors Inc. boosted its position in shares of PolyPid Ltd. (NASDAQ:PYPD) by 62.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 679,168 shares of the company’s stock after purchasing an additional 262,368 shares during the quarter. PolyPid makes up 1.5% of Rosalind Advisors Inc.’s portfolio, making the stock its 18th biggest holding. Rosalind Advisors Inc. owned 14.16% of PolyPid worth $2,336,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 26.47% of the company’s stock.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.